Member Info for Beamer21

Novacyt test only released 31/1 - sadly with the rapid rise of global infections it seems that there will be huge demand

ALL of the kits need to be run on a real time PCR and Primerdesign claim to sell the worlds most affordable qPCR at £5300 a pop - another nice revenue stream

Comek - correct the £5.44 tests will only work if you buy the q16 real time PCR instrument at a cost of £5300 per unit

Other tests available running on other instruments

Delboy, I understand your point but it’s simply all about momentum and sentiment at the moment - fundamentals will become clearer later down the line giving scope to provide a genuine valuation

Jarv, absolutely agree plus the real momentum will be for clinical testing imo

I don’t hold here currently but it seems all of the preliminary disputes over test quantities are somewhat irrelevant as at the current time NCYT is trading on sentiment and expectations of future orders - if their test was released 31/1 and 1 week later they have 33k confirmed orders with current quotations for 32k across 30 countries it would seem that given reports of a much more widespread global this could be just the tip of the iceberg - add in the CE-Mark approval and FDA temporary approval for CLINICAL testing in the US then sales could go through the roof potentially outstripping supply.

No it hasn’t - a small UT trade has skewed the overriding sp temporarily

It’s anticipated that the go ahead will be given this week after a leaked copy of the Oakervee review recommended it

5.17%

On the basis of this news I think many more investors will be considering reinvesting their divis paid on 14/2

The four SAS operators are CommScope, Federated Wireless, Google and Sony. Last year, the FCC approved these administrators for initial commercial deployments of the so-called Citizens Broadband Radio Service in the band, and now they are allowed to make full commercial use of the mid-band spectrum for broadband connectivity and 5G.

Have been relentlessly driving this all day

Thanks for posting Scott - should put NuckyT’s mind at rest

Look at the recent individual investment valuations, Crystal Ambers narrative and why there has been some chunky director buys recently

Interested in why Joseph Pignato has effectively doubled his holding since Nov 19 with the majority bought following Crystal Amber withdrawing their GM requisition

A play on words?

Nice to see Norges calling back shares out on loan - should see some upwards movement shortly

Initial broker target for slimmed down group 190p

Zero debt and around £225m in cash as they used sale proceeds of £300m to clear the slate - very undervalued currently particularly with a burgeoning high quality £3.2bn order book that’s set to expand as the government free up more cash that they’ve pledged for infrastructure

Cash alone worth £2 before anything else is factored in

Immupharma is not a one trick pony

Is there an intentional pun in your statement:-)